These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 24666338)
1. Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. Chiew AL; Khamoudes D; Chan BS Clin Toxicol (Phila); 2014 Apr; 52(4):283-7. PubMed ID: 24666338 [TBL] [Abstract][Full Text] [Related]
2. Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man. Montaruli B; Erroi L; Vitale C; Berutti S; Cosseddu D; Sivera P; Coglitore R; Marangella M; Migliardi M Blood Coagul Fibrinolysis; 2015 Mar; 26(2):225-9. PubMed ID: 25629417 [TBL] [Abstract][Full Text] [Related]
3. [The effects of continuous renal replacement therapy (CRRT) and intermittent haemodialysis (IHD) in the treatment of dabigatran overdose. Case report]. Vitale C; Berutti S; Montaruli B; Cosseddu D; Sivera P; Verdecchia C; Migliardi M; Marangella M G Ital Nefrol; 2014; 31(2):. PubMed ID: 24777926 [TBL] [Abstract][Full Text] [Related]
4. Removal of dabigatran by hemodialysis. Chang DN; Dager WE; Chin AI Am J Kidney Dis; 2013 Mar; 61(3):487-9. PubMed ID: 23219111 [TBL] [Abstract][Full Text] [Related]
5. Positive outcome after intentional overdose of dabigatran. Woo JS; Kapadia N; Phanco SE; Lynch CA J Med Toxicol; 2013 Jun; 9(2):192-5. PubMed ID: 23212788 [TBL] [Abstract][Full Text] [Related]
6. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166 [TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Stangier J; Rathgen K; Stähle H; Gansser D; Roth W Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785 [TBL] [Abstract][Full Text] [Related]
8. Idarucizumab for dabigatran overdose. Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445 [TBL] [Abstract][Full Text] [Related]
9. Enhanced elimination of dabigatran through extracorporeal methods. Awad NI; Brunetti L; Juurlink DN J Med Toxicol; 2015 Mar; 11(1):85-95. PubMed ID: 25448250 [TBL] [Abstract][Full Text] [Related]
10. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Bouchard J; Ghannoum M; Bernier-Jean A; Williamson D; Kershaw G; Weatherburn C; Eris JM; Tran H; Patel JP; Roberts DM Clin Toxicol (Phila); 2015 Mar; 53(3):156-63. PubMed ID: 25661675 [TBL] [Abstract][Full Text] [Related]
11. Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. Chen BC; Sheth NR; Dadzie KA; Smith SW; Nelson LS; Hoffman RS; Winchester JF Am J Kidney Dis; 2013 Sep; 62(3):591-4. PubMed ID: 23597859 [TBL] [Abstract][Full Text] [Related]
12. Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. Porru M; Mameli A; Cianchetti ME; Musu M; Schirru P; Ruberto MF; Barcellona D; Marongiu F Int J Hematol; 2017 Apr; 105(4):532-535. PubMed ID: 27910004 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075 [TBL] [Abstract][Full Text] [Related]
14. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Stangier J; Rathgen K; Stähle H; Mazur D Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409 [TBL] [Abstract][Full Text] [Related]
15. An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. Wilson JA; Goralski KB; Soroka SD; Morrison M; Mossop P; Sleno L; Wang Y; Anderson DR J Clin Pharmacol; 2014 Aug; 54(8):901-9. PubMed ID: 24846496 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715 [TBL] [Abstract][Full Text] [Related]
17. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Béné J; Saïd W; Rannou M; Deheul S; Coupe P; Gautier S Ann Pharmacother; 2012 Jun; 46(6):e14. PubMed ID: 22669799 [TBL] [Abstract][Full Text] [Related]
18. [Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. Bachellerie B; Ruiz S; Conil JM; Crognier L; Seguin T; Georges B; Fourcade O Ann Fr Anesth Reanim; 2014 Jan; 33(1):44-6. PubMed ID: 24378048 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. Trocóniz IF; Tillmann C; Liesenfeld KH; Schäfer HG; Stangier J J Clin Pharmacol; 2007 Mar; 47(3):371-82. PubMed ID: 17322149 [TBL] [Abstract][Full Text] [Related]
20. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Wanek MR; Horn ET; Elapavaluru S; Baroody SC; Sokos G Ann Pharmacother; 2012 Sep; 46(9):e21. PubMed ID: 22872748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]